BioIVT, a leading provider of biospecimens and ADME-Tox research products and services for drug and diagnostic development, today announced that it will be hosting an Advanced In Vitro ADME Strategies Symposium at the Scandic CPH Strandpark Hotel in Copenhagen, Denmark on June 9.
Symposium presenters will provide insights into how the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) M12 Drug Interaction Studies Guideline, which will replace analogous guidance from ICH member countries in 2024, may impact ADME strategies.
Speakers from Novo Nordisk, Ferring Pharmaceuticals, AstraZeneca, and BioIVT will also discuss their research utilizing novel in vitro ADME methodologies. Several new models and applications developed using BioIVT’s HEPATOPAC® technology, 3D cultures and TRANSPORTER CERTIFIED® cryoplateable hepatocytes will be described.
“We are delighted to organize this event where our colleagues in the research community can come together and share scientific knowledge, gain insights, and uncover new opportunities to collaborate. At this year’s symposium, attendees will learn more about how other researchers use the cells and tools that we provide to develop unique ADME models that answer specific research questions,” said Dr. Darina Hynes, BioIVT’s Technical Sales Specialist for Europe.
“As drug researchers are adopting new tools with increasing complexity, it is even more important that they have a robust ADME strategy which incorporates all their R&D objectives and the latest regulatory guidance. We are proud to offer this educational session on ICH M12 to help our clients stay prepared,” said Dr. Brian Ogilvie, VP of Scientific Consulting at BioIVT.
Additional information about BioIVT’s comprehensive ADME products and services can be found at www.bioivt.com.
Further details about this symposium are available at EU Seminar – BioIVT Event Page. Pre-registration is required to attend this complimentary event.
About BioIVT
BioIVT enables smarter science and accelerates medical breakthroughs by delivering high-quality personalized biospecimen solutions and research services to the life science and diagnostic industries. Recognized as an industry leader, BioIVT specializes in control and disease state samples including human and animal tissues or preparations, ADME-Tox products and research services, cell and gene therapy products, blood, and other biofluids. By combining technical expertise and exceptional customer service with unmatched access to biological specimens, BioIVT serves the research community as a trusted partner in ELEVATING SCIENCE®. For more information, please visit www.bioivt.com or follow the company on Twitter @BioIVT.